Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $44.7 million.

  • Exagen's Total Liabilities rose 4537.85% to $44.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.7 million, marking a year-over-year increase of 4537.85%. This contributed to the annual value of $35.1 million for FY2024, which is 262.48% up from last year.
  • Per Exagen's latest filing, its Total Liabilities stood at $44.7 million for Q3 2025, which was up 4537.85% from $37.7 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's Total Liabilities peaked at $45.9 million during Q1 2022, and registered a low of $30.7 million during Q3 2024.
  • Over the past 5 years, Exagen's median Total Liabilities value was $36.9 million (recorded in 2021), while the average stood at $37.7 million.
  • As far as peak fluctuations go, Exagen's Total Liabilities tumbled by 2882.42% in 2024, and later surged by 4537.85% in 2025.
  • Exagen's Total Liabilities (Quarter) stood at $38.5 million in 2021, then grew by 13.64% to $43.8 million in 2022, then decreased by 21.73% to $34.2 million in 2023, then rose by 2.62% to $35.1 million in 2024, then grew by 27.13% to $44.7 million in 2025.
  • Its Total Liabilities was $44.7 million in Q3 2025, compared to $37.7 million in Q2 2025 and $33.9 million in Q1 2025.